Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03127943 · ClinicalTrials.gov registry record · Phase 4

Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine

A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 4
Development phase
24
Enrollment target

NCT03127943: Completed Phase 4 study, sponsored by University of North Carolina, Chapel Hill.

NCT03127943 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03127943, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 4
Development phase
24 participants
Enrollment target

Study Summary

Assess the clinical impact of Buffered 1% lidocaine with epinephrine as compared to the Non-buffered 1% lidocaine with epinephrine in dental and oral surgical procedures.

Primary Outcome

Subjects' mandibular molar teeth will be tested before anesthetic and every 30 minutes with cold and electric pulp test for presence of anesthesia as reported by subjects yes or no

Interventions

  • DRUG Lidocaine

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2017-05-01
Est. Completion 2018-04-01
Phase Phase 4

What the finished NCT03127943 record still lists

NCT03127943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Lidocaine is the first listed.

NCT03127943 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03127943 about?

NCT03127943 is a clinical study titled "Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine". Assess the clinical impact of Buffered 1% lidocaine with epinephrine as compared to the Non-buffered 1% lidocaine with epinephrine in dental and oral surgical procedures.

What is the current status of trial NCT03127943?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2017-05-01. Estimated completion is 2018-04-01.

What interventions are being tested in trial NCT03127943?

The interventions under investigation include: Lidocaine (DRUG).

Who is sponsoring clinical trial NCT03127943?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03127943's enrollment target sits among peer trials

24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03127943, the US trial registry maintained by the National Library of Medicine. NCT03127943 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.